[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356685-105":59,"doc-detail-356685-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","biomarkers-with-therapeutic-or-prognostic-applications-in-gynecologic-malignancies","Biomarkers with Therapeutic or Prognostic Applications in Gynecologic Malignancies","","Precision medicine for gynecologic malignancies relies on biomarker testing to guide both treatment selection and prognosis. This review summarizes the current landscape of biomarker assessment, focusing on clinical implications and testing strategies. Literature evaluation includes trials using biomarkers for inclusion criteria, prospective studies on biomarker scoring, trials linking biomarker findings to management decisions, and consensus guidelines. Biomarker testing is established as standard of care, affecting staging and therapy in endometrial cancer, recurrence-focused management in ovarian cancer, and immunotherapy decisions in cervical cancer.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarkers-with-therapeutic-or-prognostic-applications-in-gynecologic-malignancies/356685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarkers-with-therapeutic-or-prognostic-applications-in-gynecologic-malignancies/356685.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How are biomarkers used in ovarian cancer and cervical cancer?","Question",{"text":112,"@type":113},"For ovarian cancer, biomarker testing is primarily used in the recurrent setting to guide management of platinum-resistant disease, including targeted therapy with antibody drug conjugates and immunotherapy. For cervical cancer, immunotherapy is emphasized and PD-L1 testing is described as a key determinant for treatment.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},356685,1791245923,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nBiomarkers with Therapeutic or Prognostic Applications in Gynecologic Malignancies  \nMohamed Mokhtar Desouki 1,2,* and Katherine L. Mager 3  \nAcademic Editor: David Mutch  \nReceived: 18 March 2026  \nRevised: 7 April 2026  \nAccepted: 9 April 2026  \nPublished: 15 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA  \n2 Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14203, USA  \n3 Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA; [katherine.lavignemager@roswellpark.org](katherine.lavignemager@roswellpark.org)  \n* [Correspondence: mohamed.desouki@roswellpark.org](Correspondence: mohamed.desouki@roswellpark.org)  \nSimple Summary  \nTreatment of gynecologic cancer has moved to a precision medicine model with biomarkers now forming the foundation of both treatment and prognostication. These markers are assessed using multiple modalities, most commonly immunohistochemistry (IHC) and next-generation sequencing (NGS) . IHC markers are widely utilized to determine the status of estrogen receptors (ER), progesterone receptors (PR), mismatch repair proteins (MMR), Human Epidermal growth factor Receptor-2 (HER2), Folate receptor alpha (FOLR1), and p53, among others. NGS is used routinely to determine DNA Polymerase Epsilon (POLE) status in the setting of endometrial cancer and is often utilized in the setting of clinical trial eligibility across gynecologic cancers. The utilization in the laboratory of appropriate assaysand processes to accurately assess the status of these markers is crucial to the treatment of gynecologic malignancies.  \nAbstract  \nBackground/Objectives: The treatment of gynecologic malignancies has moved towards a precision medicine model with an approach to prognostication and management based on biomarker testing. The objective of this review is to describe the current landscape of biomarker testing in gynecologic cancer including clinical implications and the approach to testing. Methods: A review of the literature was performed that included published clinical trials which utilized biomarker testing as part of inclusion/exclusion criteria, prospective trials that addressed the application and scoring of biomarkers utilized in gynecologic cancers, prospective clinical trials that utilized biomarker findings to determine management, and national or society guidelines for the scoring of biomarkers and treatment of gynecologic cancers. Findings: The use of biomarker testing as part of the management of gynecologic cancers is the standard of care for both treatment and prognostication. In endometrial cancer, biomarker testing has been incorporated into the staging system and impacts treatment in both the upfront and recurrent setting. Specific biomarkers of interest for endometrial cancer include estrogen receptor (ER), progesterone receptor (PR), DNA Polymerase Epsilon (POLE), mismatch repair proteins (MMR), and Human Epidermal growth factor Receptor-2 (HER2) . In ovarian cancer, biomarker testing is primarily utilized in the recurrent setting to guide management of platinum-resistant ovarian cancer with a specific focus on targeted therapy utilizing antibody drug conjugates (ADCs) and immunotherapy. Immunotherapy has become an important component of therapy for cervical cancer and Programmed death-ligand 1 (PD-L1) testing is a key biomarker in determining treatment. Conclusions: The utilization of appropriate assays and processes to accurately  \nassess the status of biomarkers in the pathology laboratory is crucial to the treatment of gynecologic malignancies in the precision medicine era.  \nKeywords: ER; PR; Her2; MMR; P53; PD-L1; FOLR1; POLE; IHC; cl","cbCaibRPQRictYs8","https://ap.wps.com/l/cbCaibRPQRictYs8","pdf",2611697,22,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n## Biomarkers in modern pathology\n## Therapeutic, prognostic, and diagnostic applications","[{\"question\":\"How are biomarkers used in ovarian cancer and cervical cancer?\",\"answer\":\"For ovarian cancer, biomarker testing is primarily used in the recurrent setting to guide management of platinum-resistant disease, including targeted therapy with antibody drug conjugates and immunotherapy. For cervical cancer, immunotherapy is emphasized and PD-L1 testing is described as a key determinant for treatment.\"}]","Biomarkers with Therapeutic or Prognostic Applications in Gynecologic Malignancies | PDF",1790126795,55,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/932402c0c7ea5cf54cc94b807b529b72.webp",983,1390,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a02da399a4c5277cb64844951327879.webp",982,1388,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ff79eceec19391060b8cdfd70c8ceb3.webp",981,693,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7015b4534a71ebd5c7b3e6e132c93618.webp",980,1385]